Clinical Trial Update: A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial studying ZL-1310 versus investigator's choice of therapy in relapsed small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• ZL-1310

Snippet

Sponsor: Zai Lab (Shanghai) Co., Ltd. | Conditions: Small-cell Lung Cancer | Phase 3 | Status: RECRUITING